2-year ELTP chart
Predictions by some of the bashers on iHub have been eerily coming to fruition as the Elite Pharma team silently works out various concerns.
However, the company has been profitable and if some of the issues get worked out there could be a nice rebound. Investors wait for the time, but at .092/share, there is reason for concern.
ELTP really needs some positive FDA news, but every day seems more and more difficult to trust.
No comments:
Post a Comment